Andrew Robert Branagan

Denosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study

Lytic bone lesions are a defining characteristic of multiple myeloma (MM) and one of its most significant clinical consequences. Bone-modifying agents, including the bisphosphonates zoledronic acid and pamidronate, as well as the receptor activator of nuclear factor-κB ligand (RA...

Impact of initial dosing and subsequent dose reduction of zanubrutinib in patients with Waldenström macroglobulinemia

Zanubrutinib is the preferred Bruton tyrosine kinase inhibitor for Waldenström macroglobulinemia (WM), yet data on dosing strategies remain limited. We evaluated 236 WM patients who received zanubrutinib monotherapy between 2018 and 2025. We assessed the impact of initial dosing...